12,372 trials
Infections, Papillomavirus
Primary: Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines — 877.4; 19.5; 738.5; 22.3 cells per million CD4/CD8 T-cells
Cataracts
Primary: Percent Loss of Endothelial Cells — 9.48; 15.66; 23.69; 25.70 Percent Loss
Rhinitis, Allergic, Seasonal
Primary: The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Phenylephrine Compared With Placebo — 2.20; 2.20; -0.12; -0.18 Units on a…
Schizophrenia
Primary: Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio) — -0.08; 0.42 Ratio — p=< 0.0001
Obstructive Sleep Apnea · Hypopnea
Primary: Maintenance of Wakefulness Test (MWT) — 2.2; 1.7; -1.7 Minutes — p=0.0001
Bipolar Disorder
Primary: Time to Withdrawal From Study — 67.5 days — p=0.010
Influenza
Primary: Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains — 10.4; 10.6; 10.9; 106.1 titre
Influenza
Primary: Hemagglutination Inhibition (HI) Antibody Titer — 15.5; 11.4; 139.7; 55.8 titer
Low Back Pain
Primary: The Difference in the Mean Average Pain Intensity Score on an 11-point Numerical Rating Scale (NRS) During the Last 3 Days of Each Double-blind Treatment Period…
Relapsing Multiple Sclerosis
Primary: Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu-like Symptom Score — 8.5; 9.1 MSTCQ score (units on a scale)
Diabetes Mellitus, Type 2 · Chronic Renal Insufficiency
Primary: Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment — 41; 16; 8; 1 Participants
Rotavirus · Gastroenteritis
Primary: Number of Participants With Rotavirus Gastroenteritis of Any Severity Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A — 7; 27…
Migraine Headache
Primary: Pain Relief at 2 Hours After Treatment — 223; 238; 18; 129 Participants
Pompe Disease (Late-onset) · Glycogen Storage Disease Type II (GSD-II) · Acid Maltase Deficiency Disease
Primary: Summary of Patients Reporting Treatment-Emergent Adverse Events — 60; 30; 32; 17 participants
Pain · Osteoarthritis · Low Back Pain
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAE) — 907 participants